Preferred Label : Sitravatinib Malate;
NCIt definition : The malate form of sitravatinib, an orally bioavailable, receptor tyrosine kinase
(RTK) inhibitor, with potential antineoplastic activity. Upon administration, sitravatinib
binds to and inhibits the activity of several RTKs including hepatocyte growth factor
receptor (HGFR; c-Met; MET), tyrosine-protein kinase receptor UFO (AXL receptor tyrosine
kinase; AXL), mast/stem cell growth factor receptor (SCFR; c-kit; KIT), the receptor
tyrosine kinase MER, discoidin domain receptor 2 (DDR2), vascular endothelial growth
factor receptor (VEGFR) types 1 (VEGFR-1; FLT1), 2 (VEGFR-2; KDR; Flk-1) and 3 (VEGFR-3),
members of the platelet-derived growth factor receptor (PDGFR) family, RET (rearranged
during transfection), tropomyosin-related kinases (TRK) and members of the ephrin
(Eph) family of receptor tyrosine kinases. This may result in both the inhibition
of signal transduction pathways mediated by these RTKs and the reduction of tumor
cell proliferation in cancer cell types that overexpress these RTKs.;
UNII : ZR2110H6XE;
InChIKey : GDLGZWLGDROYHH-WNQIDUERSA-N;
CAS number : 2244864-88-6;
NCI Metathesaurus CUI : CL1405880;
Origin ID : C171930;
UMLS CUI : C5419371;
Semantic type(s)
- concept_is_in_subset
- has_free_acid_or_base_form
- is_salt_form_of
